New vaccine combo aims to outsmart ovarian cancer resistance

NCT ID NCT05479045

Not yet recruiting Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a peptide vaccine (NY-ESO-1) combined with an immunotherapy drug (toripalimab-tpzi) can prevent resistance to treatment in 24 women with stage III/IV ovarian cancer that no longer responds to platinum chemotherapy. The vaccine primes the immune system, while the drug boosts its attack on cancer cells. Researchers will measure how long the cancer stays controlled and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NY-ESO-1 peptide vaccine combined with toripalimab-tpzi (an immunotherapy drug)
What this could lead to: If it works, this could help control advanced ovarian cancer by preventing resistance to immunotherapy, potentially extending life for patients who have run out of standard options.
What could go wrong: This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The vaccine and drug combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER STAGE 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER STAGE 3 OVARIAN CANCER STAGE III OVARIAN CANCER STAGE IV

Contacts and locations

Locations

John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.